Etienne Cavalier
Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Etienne Cavalier is a Professor at Université de Liège, Belgium. His research focuses on the assessment of measurement uncertainty in various medical testing methods, the role of vitamin D in health, and factors predicting outcomes in chronic kidney disease and hemodialysis patients. He has recently published articles on topics such as immunoassays, nutritional vitamin D's role in chronic health conditions, and the differentiation of psoriatic arthritis from osteoarthritis.
Articles (29)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Background The use of interstitial glucose monitoring devices such as Flash Glucose Monitoring has been shown to be beneficial in patients with type 1 diabetes (T1DM). However, these devices have been little studied in patients with diabetes treated by chronic haemodialysis (HD). Methods The goal of this prospective, observational, multicentric, study was to evaluate the analytical performance of the FreeStyle Libre® 2 (FSL2) sensor in T1DM patients during HD sessions. During three HD sessions, interstitial glucose concentrations (ISFG) given by the FSL2 were compared, every 15 minutes, with blood glucose concentration (BG) obtained simultaneously. BG concentrations were measured by two different glucometers: the Accu-Chek Guide® and the StatStrip® meter. Results Twelve hemodialysis patients were included. Mean age was 54 ± 11 years. Mean diabetes duration was 36.5 ± 11.6 years and dialysis vintage was 35 ± 22 months. A total of 565 pairs of ISFG/BG values were available for analysis. The mean absolute relative difference, defined as the mean of the absolute relative differences between the ISFG and BG measurements, was 17.4% and 20.9% when the ISFG were compared to the StatStrip glucometer or Accu-Chek Guide, respectively. Interstitial results tend to underestimate blood results but all values were classified as having clinically acceptable error. The differences observed remained stable during the dialysis session and were not associated with the ultrafiltration rate. Conclusion The use of the FSL2 interstitial glucose monitoring device in HD patients with T1DM is clinically acceptable, even though the accuracy of the device is generally poorer than in studies including non-dialysis patients.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (19)
Olivier Moranne
University of Montpellier
Joe El-Khoury
Assistant Professor
Yale University
Pierre Delanaye
University of Liege
Elena Levtchenko
prof. dr.
-
Kate Ward
Professor of Global Musculoskeletal Health
University of Southampton
Amy Karger
University of Minnesota
Giorgio Bedogni
Associate Professor of Internal Medicine
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Marc Vervloet
Associate professor
University of Amsterdam
Tomris Ozben
-
Aurélie Ladang
University of Liege
Emma Calluy
University of Namur
Sandro Mazzaferro
Full Professor of Nephrology
Sapienza University of Rome
Harjit Pal Bhattoa
Associate Professor
University of Debrecen Medical School and Health Science Center
Mandy Wan
King’s College London
Callum G Fraser
University of Dundee
David Friedecký
-
Manuel Diaz-Curiel
Associate Chief
-
Hanne Mari Skou Jørgensen
Associate Professor
Aarhus University
Thomas Stehlé
-
Make your next move.
Prepare your application
Review drafts before you send them.